ClinicalTrials.Veeva

Menu

Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality

Thomas Jefferson University logo

Thomas Jefferson University

Status

Suspended

Conditions

Head and Neck Squamous Cell Carcinoma

Treatments

Other: Medical Device Usage and Evaluation
Procedure: Resection
Other: Best Practice

Study type

Interventional

Funder types

Other

Identifiers

NCT05031910
21D.079
JT 15475 (Other Identifier)

Details and patient eligibility

About

This clinical trial studies the use of virtual reality technology and three dimensional surgery (3D-surgery) modeling to enhance current treatments in head and neck cancer surgery. Virtual reality 3D-surgery modeling may improve quality of surgical planning and interdisciplinary communication between surgeons and pathologists during the treatment of head and neck squamous cell cancer and ultimately increase the accuracy of planning, the quality of communication, and maximize the outcome patients with head and neck cancer experience throughout treatment.

Full description

PRIMARY OBJECTIVES:

To assess the potential for preoperative virtual reality and 3D pathological modeling to reduce total number of margin events as defined in the study as the number of positive frozen margins, number of positive final margins and the number of unexpected defect driven margins.

SECONDARY OBJECTIVES:

To assess the impact of preoperative virtual reality and 3D pathologic modeling as treatment for head and neck squamous cell carcinoma on event free survival (EFS) at 18-36 months after resection as defined by recurrence at the primary site.

TERTIARY OBJECTIVE:

I. To evaluate the quality of existing interdisciplinary intraoperative communication using the proposed VR/3D-case enhancement protocols (CEPs) as an evaluating medium.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I (VR/3D-CEPs + STANDARD TREATMENT): Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical computed tomography (CT) scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.

ARM II (STANDARD TREATMENT): Prior to surgery (day 0-13), patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29.

After completion of study intervention, patients are followed for up to 36 months.

Enrollment

160 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed with cancer of the head and neck (oral cavity, oropharynx, larynx, hypopharynx, T1-T4)
  • Receiving treatment at Thomas Jefferson University - Center City by a fellowship-trained HNC surgeon
  • Eligible for definitive resection
  • Age > 18
  • Provide signed written informed consent document

Exclusion criteria

  • Impaired judgement or those unable to provide informed consent
  • Any factor that would place the patient at increased risk or preclude the individual's full compliance with or completion of the study
  • Nasopharyngeal carcinoma
  • Contraindications for surgery
  • Enrollment in other clinical trial

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

160 participants in 2 patient groups

Arm I (VR/3D-CEPs, standard treatment)
Experimental group
Description:
Prior to surgery (day 0-13), patients undergo virtual reality 3D tumor resection via VR/3D-CEPs. Patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29 and a 3D model of true tumor is created and imported into the virtual reality environment.
Treatment:
Other: Best Practice
Procedure: Resection
Other: Medical Device Usage and Evaluation
Arm II (standard treatment)
Active Comparator group
Description:
Prior to surgery (day 0-13), patients' pre-surgical CT scans are reviewed per standard of care. Patients then undergo surgical resection on day 14-29.
Treatment:
Other: Best Practice
Procedure: Resection

Trial contacts and locations

1

Loading...

Central trial contact

Joseph Curry, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems